Jon Salmanton-García1, Philipp Koehler2, Anupma Kindo3, Iker Falces-Romero4, Julio García-Rodríguez4, Zdeněk Ráčil5, Sharon C-A Chen6, Nikolai Klimko7, Guillaume Desoubeaux8, George R Thompson9, Miguel-Ángel Benítez-Peñuela10, José-Yesid Rodríguez10, Donald C Sheppard11, Martin Hoenigl12, Yohann Le Govic13, Hamid Badali14, John W Baddley15, Jagdish Chander16, Paul R Ingram17, Diana L Pakstis18, Sibylle C Mellinghoff19, Serkan Atıcı20, Simone Cesaro21, Arunaloke Chakrabarti22, Damien Dupont23, Gloria M González24, Lóránt Hatvani25, Raoul Herbrecht26, Galina Klyasova27, Cornelia Lass-Flörl28, Mihai Mareș29, Kathleen Mullane30, Donald C Vinh31, Hilmar Wisplinghoff32, Michaela Lackner28, Oliver A Cornely33, Danila Seidel34. 1. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Excellence Center for Medical Mycology (ECMM), Herderstrasse 52-54, 50931 Cologne, Germany. Electronic address: jon.salmanton-garcia@uk-koeln.de. 2. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Excellence Center for Medical Mycology (ECMM), Herderstrasse 52-54, 50931 Cologne, Germany; University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. 3. Department of Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India. 4. Clinical Microbiology and Parasitology Department, University Hospital La Paz, Madrid, Spain. 5. Department of Internal Medicine-Hematology and Oncology, Masaryk University, Brno, Czech Republic; University Hospital Brno, Brno, Czech Republic; Institute of Hematology and Blood Transfusion, Prague, Czech Republic. 6. Centre for Diseases and Microbiology Laboratory Services, ICPMR, New South Wales Health Pathology, Westmead Hospital, Sydney, NSW, Australia; The University of Sydney, Westmead, Sydney, NSW, Australia. 7. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation. 8. Parasitologie - Mycologie - Médecine Tropicale, CHU de Tours, France; Centre d'Etude des Pathologies Respiratoires - Unité Inserm U1100, Université de Tours, Tours, France. 9. Department of Internal Medicine Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, United States; Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, CA, United States. 10. Center of Microbiological Research of Cesar (CIMCE), Rosario Pumarejo de López Hospital, Laura Daniela Clinic, Médicos Clinic LTDA, Valledupar, Colombia. 11. Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. 12. Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA, United States; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, United States; ECMM Excellence Center for Clinical Mycology, Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical University of Graz, Graz, Austria. 13. Parasitology-Mycology Unit, University Hospital Center, Fort-de-France, Martinique, French West Indies. 14. Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. 15. Department of Internal Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL, United States; Medical Service, Birmingham VA Medical Center, AL, United States; Institute for Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States. 16. Department of Microbiology, Government Medical College and Hospital, Chandigarh, India. 17. Department of Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia; School of Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia. 18. Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Palestine, State of, United States. 19. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Excellence Center for Medical Mycology (ECMM), Herderstrasse 52-54, 50931 Cologne, Germany. 20. Department of Pediatrics, Division of Pediatric Infectious Disease, Okan University School of Medicine, Istanbul, Turkey. 21. Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata Verona, Italy. 22. Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Research, Chandigarh, India. 23. Institut des Agents Infectieux, Parasitologie Mycologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Integrative Physiology of the Brain Arousal Systems, Centre de Recherche en Neurosciences de Lyon, INSERM U1028-CNRS UMR 5292, Faculté de Médecine, Université Claude Bernard Lyon 1, Lyon, France. 24. Department of Microbiology, School of Medicine, Universidad Autonóma de Nuevo León, Nuevo León, Mexico. 25. MTA-SZTE "Lendület" Mycobiome Research Group, Szeged, Hungary; Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary. 26. Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, Inserm, UMR-S1113/IRFAC, Strasbourg, France. 27. epartment of Clinical Microbiology, Mycology and Antibiotic Therapy, National Research Center for Hematology, Moscow, Russia. 28. Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria. 29. Laboratory of Antimicrobial Chemotherapy, Ion Ionescu de la Brad University, Iași, Romania. 30. Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago, Chicago, IL, United States. 31. Research Institute - McGill University Health Centre, Infectious Diseases and Immunity in Global Health Program, Montreal, QC, Canada. 32. Wisplinghoff Laboratories, Cologne, Germany; Institute for Medical Microbiology, University of Cologne, Cologne, Germany; Institute for Virology and Microbiology, Witten/Herdecke University, Witten, Germany. 33. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Excellence Center for Medical Mycology (ECMM), Herderstrasse 52-54, 50931 Cologne, Germany; German Centre for Infection Research (DZIF), partner site Bonn - Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. 34. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Excellence Center for Medical Mycology (ECMM), Herderstrasse 52-54, 50931 Cologne, Germany. Electronic address: danila.seidel@uk.koeln.de.
Abstract
OBJECTIVES: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. METHODS: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. RESULTS: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. CONCLUSIONS: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.
OBJECTIVES: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. METHODS: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. RESULTS: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. CONCLUSIONS: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.
Authors: Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks Journal: Drugs Date: 2021-10-09 Impact factor: 9.546
Authors: Stephen M Maurer; Kathleen A Linder; Carol A Kauffman; Philip J McDonald; Jonathan Arcobello; Jon Velasco; Pranatharthi H Chandrasekar; Sanjay G Revankar; Marisa H Miceli Journal: Bone Marrow Transplant Date: 2022-09-23 Impact factor: 5.174
Authors: Dierdre B Axell-House; Sebastian Wurster; Ying Jiang; Andreas Kyvernitakis; Russell E Lewis; Jeffrey J Tarrand; Issam I Raad; Dimitrios P Kontoyiannis Journal: J Fungi (Basel) Date: 2021-03-17